摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-Diphenyl-buttersaeure-methylester | 10347-50-9

中文名称
——
中文别名
——
英文名称
4,4-Diphenyl-buttersaeure-methylester
英文别名
Methyl 4,4-diphenylbutanoate
4,4-Diphenyl-buttersaeure-methylester化学式
CAS
10347-50-9
化学式
C17H18O2
mdl
——
分子量
254.329
InChiKey
KONORNDPKQTLGG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    190-192 °C(Press: 12 Torr)
  • 密度:
    1.063±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4,4-Diphenyl-buttersaeure-methylester 在 lithium aluminium tetrahydride 、 三乙胺 作用下, 以 乙醚氯仿 为溶剂, 反应 24.0h, 生成 4,4-diphenylbutyl 4-methylbenzenesulfonate
    参考文献:
    名称:
    New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance
    摘要:
    Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.01.024
  • 作为产物:
    描述:
    2-(2,2-二苯基乙基)丙二酸 在 硫酸 作用下, 以 氯仿 为溶剂, 反应 5.0h, 生成 4,4-Diphenyl-buttersaeure-methylester
    参考文献:
    名称:
    New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance
    摘要:
    Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.01.024
点击查看最新优质反应信息

文献信息

  • Development of efficient palladium catalysts for alkoxycarbonylation of alkenes
    作者:Jiawang Liu、Kaiwu Dong、Robert Franke、Helfried Neumann、Ralf Jackstell、Matthias Beller
    DOI:10.1039/c8cc07470d
    日期:——
    report a general and efficient Pd-catalysed alkoxycarbonylation of sterically hindered and demanding olefins including a variety of tri-, tetra-substituted and 1,1-disubstituted alkenes. In the presence of 1,3-bis(tert-butyl(pyridin-2-yl)phosphanyl)propane L3 or 1,4-bis(tert-butyl(pyridin-2-yl)phosphanyl)butane L4 the desired esters are obtained in good yields and selectivities. Similar transformation
    在本文中,我们报道了空间受阻和苛刻的烯烃(包括各种三,四取代和1,1-二取代的烯烃)的一般有效的Pd催化烷氧基羰基化反应。在1,3-双(叔丁基(吡啶-2-基)膦酰基)丙烷L3或1,4-双(叔丁基(吡啶-2-基)膦酰基)丁烷L4的存在下,获得所需的酯。具有良好的收率和选择性。如MTBE羰基化为相应的线性酯所显示的,使用叔醚以高收率和选择性获得了类似的转化。
  • Photochemical addition of tertiary amines to electrophilic cyclopropanes via single electron transfer
    作者:Hideo Tomioka、Hiroshi Miyagawa
    DOI:10.1039/c39880001183
    日期:——
    Irradiation of arylcyclopropanes bearing at least one electron-withdrawing group with a tertiary amine in acetonitrile resulted in the formation of the regioselective addition product of the amine along with the reduction product.
    在乙腈中用叔胺辐照带有至少一个吸电子基团的芳基环丙烷会导致胺的区域选择性加成产物与还原产物一起形成。
  • S1P3受容体拮抗薬
    申请人:トーアエイヨー株式会社
    公开号:JP2005247691A
    公开(公告)日:2005-09-15

    PROBLEM TO BE SOLVED: To obtain a compound having selective SIP3 receptor antagonism and a medicine containing the same.

    SOLUTION: The medicine comprises an aminopropionic acid derivative represented by general formula (1) (R1is a hydrogen atom or a lower alkyl group; R2is formula A; A is CO or CH2; E is an oxygen atom or an NR4; R3is a lower alkyl group or formula B; G is CH, a nitrogen atom or a phosphorus atom; J is an oxygen atom or a sulfur atom; R4is a hydrogen atom or a lower alkyl group; R5, R6and R7are each the same or different and a hydrogen atom, a lower alkyl group, a lower alkoxy group, a halogen atom, a nitro group or a haloalkyl group; m is an integer of 1-8; n is an integer of 1-5) or its pharmaceutically permissible salt as an active ingredient.

    COPYRIGHT: (C)2005,JPO&NCIPI

    需要解决的问题:获得具有选择性SIP3受体拮抗作用的化合物和含有该化合物的药物。 解决方案:所述药物包含一种由通式(1)表示的氨基丙酸衍生物(其中R1为氢原子或较低的烷基;R2为公式A;A为CO或CH2;E为氧原子或NR4;R3为较低的烷基或公式B;G为CH、氮原子或磷原子;J为氧原子或硫原子;R4为氢原子或较低的烷基;R5、R6和R7分别相同或不同,为氢原子、较低的烷基、较低的烷氧基、卤素原子、硝基或卤代烷基;m为1-8的整数;n为1-5的整数),或其药学上可接受的盐作为活性成分。 版权所有:(C)2005,JPO&NCIPI
  • Goldschmidt,S.; Beer,L., Justus Liebigs Annalen der Chemie, 1961, vol. 641, p. 40 - 50
    作者:Goldschmidt,S.、Beer,L.
    DOI:——
    日期:——
  • Wittig, Chemische Berichte, 1931, vol. 64, p. 437,442, 443
    作者:Wittig
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐